COPD exacerbations.5: management
- PMID: 16738044
- PMCID: PMC2111219
- DOI: 10.1136/thx.2005.041863
COPD exacerbations.5: management
Abstract
A review of the most relevant evidence based therapeutic options currently available for the management of exacerbations of COPD.
Conflict of interest statement
Competing interests: The author has participated as a lecturer and speaker in scientific meetings and courses under the sponsorship of Almirall, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA and Pfizer; consulted with several pharmaceutical companies with relevance to the topics discussed in the present article (Almirall, Altana, AstraZeneca, Aventis, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA, Novartis, Pfizer, Viechi and Zambon); serves on advisory boards for Almirall, Boehringer Ingelheim, GlaxoSmithKline, Novartis, Pfizer, Procter & Gamble and Viechi; has been sponsored for several clinical trials; and has received laboratory research support from AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, Laboratorios Dr Esteve SA, Pfizer and Procter & Gamble Ltd.
References
-
- Gunen H, Hacievliyagil S S, Kosar F.et al Factors affecting survival of hospitalised patients with COPD. Eur Respir J 200526234–241. - PubMed
-
- Barbera J A, Roca J, Ferrer A.et al Mechanisms of worsening gas exchange during acute exacerbations of chronic obstructive pulmonary disease. Eur Respir J 1997101285–1291. - PubMed
-
- Kessler R, Faller M, Fourgaut G.et al Predictive factors of hospitalization for acute exacerbation in a series of 64 patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999159158–164. - PubMed
-
- Roberts C M, Ryland I, Lowe D.et al Audit of acute admissions of COPD: standards of care and management in the hospital setting. Eur Respir J 200117343–349. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical